28 May 2012

Beca FPU

Institut de Recerca Vall d'Hebron
 Contacto correo-e:joan.sayos@vhir.org
El Grupo de Immunobiología del Centro en Investigación en Bioquímica y Biología Molecular para Nanomedicina (CIBBIM-Nanomedicina) del Hospital Universitario Vall d’Hebron en Barcelona busca candidatos para solicitar un contrato predoctoral FPU 2012.

Los candidatos deberán estar en posesión de los títulos oficiales españoles y, en su caso, de los complementos de formación, que den acceso a la fase de investigación de un programa de doctorado. El perfil es el de un licenciado en Ciencias Biológicas, Bioqumica, Bbiotecnología o similar.

Las bases de estas becas se pueden consultar en la página web:


La Tesis Doctoral se desarrollará dentro del proyecto de Investigación “Inmuno receptores CD300; Caracterización funcional e implicación en enfermedades inflamatorias desmielinizantes”.

El plazo final para solicitar la beca es el día 1 de junio de 2012.

 Información sobre el proyecto de Investigación

The CD300family of immunoreceptors is composed by six members, CD300a/IRP60, CD300b/IREM3, CD300c/CMRF35, CD300d, CD300e/IREM2 and CD300f/IREM1. All of them share an extracellular region comprising a single Ig-like domain and, with the exception of CD300a, a myeloid linage restricted pattern of expression. In addition to the expression on myeloid cells, CD300a is found in some subsets of T, B and NK cells. The Immunobiology group is focused on the study of the structure and function of the CD300 family of immune receptors, as well as in their involvement in different human pathologies.

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (SNS) that affects more than 2.5 million individuals worldwide. The first symptoms appear between 20 and 30 years and is the main neurological disease in young adults, with higher incidence in women. Although the mechanisms underlying MS pathogenesis are still unclear, it is well known that patients' blood-brain barrier allows the passage of macrophages and lymphocytes to the NHS thereby initiating an inflammatory process. This inflammatory response includes activation of microglial cells and autoimmune attack against white matter oligodendrocytes. We propose, based on previous experimental data, the study of the role of the CD300f in the pathophysiology of this disease. First, we are working in the identification of the physiological ligand for this receptor, that we know is expressed by certain cells in the SNS. Secondly, the analysis of the role of soluble forms of CD300f in the
 development of the disease by studying their expression in fluid samples of multiple sclerosis patients. Since activation of microglia and macrophages is critical in the development and expansion of MS lesions, the study of the mechanisms that regulate the activation of these cells may be of vital importance in the development of new therapeutic agents for the treatment of this disease.

Publicaciones recientes del Grupo de Investigación sobre el tema

Comas-Casellas E, Martínez-Barriocanal A, Ejarque-Ortiz, A, Miro, F,  Schwartz S Jr, Martín M, and Sayós J. CD300d is a new member of the CD300 family of receptors that regulates their surface expression. J Biol Chem. 287: 9682-9693. (2012)

Peluffo, H, Alí-Ruiz, D,  Ejarque-Ortíz, A, Heras-Alvarez, V, Comas-Casellas, E, Martínez-Barriocanal, A, Kamaid, A, Alvarez-Errico, D, Negro, ML, Lago, N, Schwartz Jr, S, Villaverde, A and  Sayós, J. Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol. 22:318-328. (2012)

Martínez-Barriocanal A, Comas-Casellas E, Schwartz S Jr, Martín M, and Sayós J. CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation. J. Biol. Chem. 285:41781-94. (2010).

No comments: